These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Haloperidol--new addition to the drug treatment of schizophrenia. Stewart A; Lafave HG; Segovia G Behav Neuropsychiatry; 1969 Oct; 1(7):23-8. PubMed ID: 4907607 [No Abstract] [Full Text] [Related]
3. New pharmacological approaches in the treatment of Tourette syndrome. Borison RL; Ang L; Chang S; Dysken M; Comaty JE; Davis JM Adv Neurol; 1982; 35():377-82. PubMed ID: 6756088 [No Abstract] [Full Text] [Related]
4. Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients. Itil TM; Polvan N; Ucok A; Eper E; Güven F; Hsu W Behav Neuropsychiatry; 1971 Dec; 3(9):6-13. PubMed ID: 4948869 [No Abstract] [Full Text] [Related]
5. Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients. Itil TM; Polvan N; Ucok A; Eper E; Güven F; Hsu W Behav Neuropsychiatry; 1971; 3(5):25-32. PubMed ID: 4948596 [No Abstract] [Full Text] [Related]
6. Integrated EEG. variability: drug effects in acute schizophrenics. Marjerrison G; Keogh RP Can Psychiatr Assoc J; 1969 Aug; 14(4):403-5. PubMed ID: 4897659 [No Abstract] [Full Text] [Related]
7. Management of hostile, suspicious patients. Trifluoperazine versus haloperidol. O'Brien CP; DiGiacomo JN; Webb W Dis Nerv Syst; 1974 Feb; 35(2):75-8. PubMed ID: 17894044 [TBL] [Abstract][Full Text] [Related]
8. Tourette syndrome associated with mental retardation: a single-subject treatment study with haloperidol. Rosenquist PB; Bodfish JW; Thompson R Am J Ment Retard; 1997 Mar; 101(5):497-504. PubMed ID: 9083606 [TBL] [Abstract][Full Text] [Related]
9. Lack of effect of 28 days of neuroleptic treatment on platelet benzodiazepine binding sites in schizophrenics. Tanne Z; Weizman R; Karp L; Katz Y; Tyano S; Gavish M Neuropsychobiology; 1987; 17(3):121-3. PubMed ID: 2825067 [TBL] [Abstract][Full Text] [Related]
10. [Gilles de la Tourette's disease]. Gonge M; Barbeau A Union Med Can; 1977 Apr; 106(4):559-70. PubMed ID: 324070 [No Abstract] [Full Text] [Related]
11. Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol. Lovett WC; Stokes DK; Taylor LB; Young ML; Free SM; Phelan DG J Clin Psychiatry; 1987 Jun; 48(6):234-6. PubMed ID: 3294815 [TBL] [Abstract][Full Text] [Related]
12. [Gilles de la Tourette's disease (report of 3 cases)]. Llanos Zuloaga R Rev Neuropsiquiatr; 1973 Dec; 36(4):222-32. PubMed ID: 4532782 [No Abstract] [Full Text] [Related]
13. Haloperidol. Med Lett Drugs Ther; 1967 Sep; 9(18):70-1. PubMed ID: 5233811 [No Abstract] [Full Text] [Related]
15. Global ratings compared to rating scales in evaluating trifluoperazine-amobarbital in anxious psychoneurotic outpatients. Bercel NA Behav Neuropsychiatry; 1971; 2(11):15-9. PubMed ID: 4935767 [No Abstract] [Full Text] [Related]
16. Gilles de la Tourette's syndrome. Shapiro AK; Shapiro E Am Fam Physician; 1974 Jun; 9(6):94-6. PubMed ID: 4524557 [No Abstract] [Full Text] [Related]
17. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749 [TBL] [Abstract][Full Text] [Related]
18. [A therapeutic pathomorphosis of schizophrenia proceeding with paranoid disorders]. Ozola MIa Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(4):600-5. PubMed ID: 5497116 [No Abstract] [Full Text] [Related]